What this is
Single filing record
This page shows the rows from one Form 4 filing as reported to the SEC.
Big buy
James Healy: large open-market buy of RAPP
$20M open-market purchase by James Healy, Director at Rapport Therapeutics,Inc., filed October 30, 2026. Learn more
Feed status Last SEC check:Loading Last Filing: Loading
View RAPP
Access Free feed
Quick read What does this view show?
Why it matters
Read the SEC filing
The original SEC document is the source record. Always verify before drawing conclusions.
How to read it
Role, size, timing
Insider activity carries more weight from senior officers, large dollar values, and clustered timing.
Stacked feeds
Key insider views at a glance
Big BuyRAPP
$24.21+7.60% today
James Healy · Director at Rapport Therapeutics,Inc.
$20M
James Healy bought $20M of RAPP (Rapport Therapeutics,Inc.).
Insider purchase
Transaction details
James Healy, a Director, reported a $20M open-market purchase equal to 1.5% of RAPP's market cap.
James Healy (Director) bought 952,380 shares of RAPP, Rapport Therapeutics,Inc., Healthcare ($1.32B market cap), at $21.00 per share on October 28, 2026 for a total of $20M (1.5% of the market cap).
James Healy
Director
Purchase value$20M
Shares purchased952,380
Price per share$21.00 per share
- % of market cap
- 1.5%
- Trade date
- October 28, 2026
- Filed
- October 30, 2026
- Filing delay
- 2 days
Permalink https://bluecollarpicks.com/insider-trading/RAPP/buy/2120238
Market context
RAPP market snapshot
Current price$24.21
1-day change+7.60%
Market cap$1.32B
SectorHealthcare
Next earningsNovember 5, 2026
$24.21
Current price$24.21
Analyst target$62.71 (+127.4%)
Last enriched October 30, 2026 at 8:06 AM EDT.
Filings
Recent insider trades
Status Loading
Latest visible filing loading.
Public Form 4 filings, normalized for cleaner scanning. What do these codes mean?
| Ticker | Type & Role | Value | |
|---|---|---|---|
| This filing | Big Buy Director | $20M | |
| $108.1K | |||
Grant Director | $0 | ||
Sell 10% Owner | $17.2M | ||
Sell 10% Owner | $17.2M | ||
Sell 10% Owner | $17.2M | ||
Sell 10% Owner | $17.2M | ||
Sell 10% Owner | $17.2M | ||
Sell 10% Owner | $17.2M | ||
Sell Officer | $808.8K | ||
Sell Officer | $357.8K | ||
Sell Officer | $320.5K | ||
Sell Officer | $17.5K | ||
Sell Officer | $12.6K | ||
Sell Officer | $58.3K | ||
| $62.6K | |||
| $68K | |||
| $86.6K | |||
| $103.2K | |||
| $10.8K | |||
| Not reported | |||
| $25.2K | |||
| $65.1K | |||
| $156.3K | |||
Grant Officer | $0 | ||
Grant CEO | $0 | ||
Grant CFO | $0 | ||
Grant Officer | $0 | ||
Grant Officer | $0 | ||
Grant Officer | $0 | ||
| $132.7K | |||
| $152.3K | |||
Sell Officer | $5.5K | ||
Sell Officer | $222.7K | ||
Sell Officer | $85.3K | ||
Grant Officer | $0 | ||
Sell Officer | $197.3K | ||
Grant Officer | $0 | ||
Sell CEO | $61.9K | ||
Sell CEO | $16K | ||
Sell CEO | $18.6K | ||
Sell CEO | $70.4K | ||
Sell CEO | $83.9K | ||
Sell CEO | $72.7K | ||
Sell Officer | $24.4K | ||
Sell Officer | $230.7K | ||
Sell Officer | $150.5K | ||
Sell CEO | $77.7K | ||
Sell CEO | $72.3K | ||
Sell CEO | $69.2K | ||
$20M
Big Buy Director
$108.1K
Grant Director
$17.2M
Sell 10% Owner
$17.2M
Sell 10% Owner
Sell 10% Owner
$17.2M
Sell 10% Owner
$17.2M
Sell 10% Owner
$17.2M
Sell 10% Owner
$808.8K
Sell Officer
$357.8K
Sell Officer
$320.5K
Sell Officer
$17.5K
Sell Officer
$12.6K
Sell Officer
$58.3K
Sell Officer
$62.6K
$68K
$86.6K
$103.2K
$10.8K
Not reported
$25.2K
$65.1K
$156.3K
Grant Officer
Grant CEO
Grant CFO
Grant Officer
$0
Grant Officer
$0
Grant Officer
$132.7K
$152.3K
$5.5K
Sell Officer
$222.7K
Sell Officer
$85.3K
Sell Officer
Grant Officer
$197.3K
Sell Officer
$0
Grant Officer
$61.9K
Sell CEO
$16K
Sell CEO
$18.6K
Sell CEO
$70.4K
Sell CEO
$83.9K
Sell CEO
$72.7K
Sell CEO
$24.4K
Sell Officer
$230.7K
Sell Officer
$150.5K
Sell Officer
$77.7K
Sell CEO
$72.3K
Sell CEO
$69.2K
Sell CEO
Cluster detail
Cluster members
Ticker context
Ticker summary
Recent insider activity for this company.
Insider detail
Insider activity
Recent transactions grouped by reporting owner.
Filters
Filters
Weekly recap
Get the easier version in your inbox.
Start with the free weekly recap. Upgrade later if you want the paid daily brief.
Free weekly recap. No login required. Unsubscribe any time.
Method Public Form 4 filings, normalized for cleaner scanning. Filtered rows stay available in All Form 4 Filings and ticker history. Which view should I use? →
Paid research tools
CSV exports are becoming a paid feature.
Join the waitlist for founding-member access to CSV exports, saved screens, and premium download tools when they open.